fielding acquisition agreement

Polish translation: umowa nabycia firmy Fielding Pharmaceutical Company

GLOSSARY ENTRY (DERIVED FROM QUESTION BELOW)
English term or phrase:fielding acquisition agreement
Polish translation:umowa nabycia firmy Fielding Pharmaceutical Company
Entered by: Frank Szmulowicz, Ph. D.

10:00 Jul 11, 2018
English to Polish translations [PRO]
Bus/Financial - Medical: Pharmaceuticals / farmakologia
English term or phrase: fielding acquisition agreement
chodzi o umowy dotyczące wprowadzania produktów leczniczych na określonych terytoriach
Lidia Lewandowska-Nayar
Poland
Local time: 17:55
umowa nabycia firmy Fielding Pharmaceutical Company
Explanation:
In December 2000, Novavax acquired privately owned Fielding Pharmaceutical Company (“Fielding”), based in St. Louis, Missouri, which sells,
markets and distributes a proprietary line of pharmaceutical products focused on women’s health. The puchase method of accounting was used to
account for the transaction.

--------------------------------------------------
Note added at 19 mins (2018-07-11 10:20:03 GMT)
--------------------------------------------------

Selling, general and administrative expenses were $4.7 million for 2001, compared to $1.3 million incurred for the same period in 2000, an increase
of $3.4 million. This increase was due to a number of factors, including the sales and marketing costs to support product sales, the increases in
personnel from the Fielding acquisition, the full effect of increases in administrative and executive employees in 2000 and 2001 to support our
growth and the initiation of commercialization activities for ESTRASORB. In addition, we also expensed approximately $700,000 for goodwill
amortization related to the Fielding acquisition and the acquisition of the AVC™ Product Line from King in January 2001 for $3.3 million. Research
and development expenses were $3.8 million in 2001 compared to $2.1 million in 2000. This $1.7 million increase in research and development
expenses is primarily due to NDA preparation and filing costs related to ESTRASORB and additional expenses to support the growth in research
and development contracts.

Product and another pharmaceutical product. NOVAVAX Product shall specifically
exclude any pharmaceutical or related products owned by NOVAVAX as a direct result of the consummation of the Fielding Acquisition Agreement (as defined in the Note Purchase Agreement) so long as any such pharmaceutical
product or related product does not include or use ESTRASORB™ or ANDROSORB™ technology or Know How.

https://ir.novavax.com/static-files/ad3a136c-e89f-4725-b701-...
Selected response from:

Frank Szmulowicz, Ph. D.
United States
Local time: 11:55
Grading comment
thanks!
4 KudoZ points were awarded for this answer



Summary of answers provided
3 +1umowa nabycia firmy Fielding Pharmaceutical Company
Frank Szmulowicz, Ph. D.


Discussion entries: 5





  

Answers


18 mins   confidence: Answerer confidence 3/5Answerer confidence 3/5 peer agreement (net): +1
umowa nabycia firmy Fielding Pharmaceutical Company


Explanation:
In December 2000, Novavax acquired privately owned Fielding Pharmaceutical Company (“Fielding”), based in St. Louis, Missouri, which sells,
markets and distributes a proprietary line of pharmaceutical products focused on women’s health. The puchase method of accounting was used to
account for the transaction.

--------------------------------------------------
Note added at 19 mins (2018-07-11 10:20:03 GMT)
--------------------------------------------------

Selling, general and administrative expenses were $4.7 million for 2001, compared to $1.3 million incurred for the same period in 2000, an increase
of $3.4 million. This increase was due to a number of factors, including the sales and marketing costs to support product sales, the increases in
personnel from the Fielding acquisition, the full effect of increases in administrative and executive employees in 2000 and 2001 to support our
growth and the initiation of commercialization activities for ESTRASORB. In addition, we also expensed approximately $700,000 for goodwill
amortization related to the Fielding acquisition and the acquisition of the AVC™ Product Line from King in January 2001 for $3.3 million. Research
and development expenses were $3.8 million in 2001 compared to $2.1 million in 2000. This $1.7 million increase in research and development
expenses is primarily due to NDA preparation and filing costs related to ESTRASORB and additional expenses to support the growth in research
and development contracts.

Product and another pharmaceutical product. NOVAVAX Product shall specifically
exclude any pharmaceutical or related products owned by NOVAVAX as a direct result of the consummation of the Fielding Acquisition Agreement (as defined in the Note Purchase Agreement) so long as any such pharmaceutical
product or related product does not include or use ESTRASORB™ or ANDROSORB™ technology or Know How.

https://ir.novavax.com/static-files/ad3a136c-e89f-4725-b701-...

Frank Szmulowicz, Ph. D.
United States
Local time: 11:55
Native speaker of: Native in EnglishEnglish, Native in PolishPolish
PRO pts in category: 237
Grading comment
thanks!

Peer comments on this answer (and responses from the answerer)
agree  Marcin Pustkowski
2 hrs
  -> My deep gratitude, Marcin.
Login to enter a peer comment (or grade)



Login or register (free and only takes a few minutes) to participate in this question.

You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.

KudoZ™ translation help

The KudoZ network provides a framework for translators and others to assist each other with translations or explanations of terms and short phrases.


See also:

Your current localization setting

English

Select a language

Term search
  • All of ProZ.com
  • Term search
  • Jobs
  • Forums
  • Multiple search